Dimension Capital β 2025 Investments
4 investments dated 2025 Β· listed companies and verified rows first Β· show all
NewLimit develops epigenetic reprogramming medicines to extend healthspan and treat age-related diseases at the intersection of computer science and biotechnology.
AI & Machine LearningBiotechLongevitySouth San Francisco, US
Brian Armstrong(Co-founder, Board of Directors)inBlake Byers(Director)inJacob Kimmel(Director)inMichael Polansky(Executive Officer)
Board seatZavain DarΒ· per SEC Form D
Co-investorsS32Valor Equity Partners8VCAbstract Venturesage1Beyond Capital+6 more
Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.
BiotechMedical DevicesCambridge, US
Gary D Glick(Executive Officer, Director)in
BoardJill Carroll(Director)inCarl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)Charles Baum(Director)
Board seatNan LiΒ· per SEC Form D
Co-investorsActivant CapitalBalderton CapitalCatalio Capital Management, LPForesite CapitalGlobal BioAccess FundGreatPoint Ventures+6 more
Fiveonefour builds tooling focused on agent experience (AX), helping developers ship software that AI agents can use effectively.
AI & Machine LearningDeveloper ToolsSaaSPortland, US
Timote Gelinas Delisle(Executive Officer, Director, Promoter)Chris Crane(Founder)inNicolas Joseph(Founder)inChristopher M Crane(Director)
BoardNan Li(Director)
Co-investorsFlybridge Capital PartnersVermilion Cliffs VenturesRidge VenturesStage 2 Capital
Tamarind provides a computational platform for protein and molecular engineering, offering AI and physics-based tools to design antibodies, peptides, enzymes, and small molecules.
AI & Machine LearningBiotechDeep TechEnterprise SoftwareSaaSSan Francisco, US
Deniz Kavi(Co-founder & CEO)inSherry Liu(Founder)in
Co-investorsTreeo VCY Combinator468 Capital
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.